Religious Exemption Rate for Vaccination Up in 2017 to 2018
Number of religious exemptions increased after personal belief exemption eliminated in Vermont
Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis
Percentage of FEV1 higher at four weeks and through 24 weeks with treatment versus placebo
Risk for Birth Defects Not Increased With Adalimumab
Risk for preterm delivery higher in women with RA, Crohn disease regardless of adalimumab exposure
Equivalence Seen Between Drug Classes for HTN Monotherapy
Thiazide, thiazide-like diuretics superior to ACEi; nondihydropyridine calcium channel blockers inferior
Increase Seen in Opioid-, Synthetic Opioid-Involved OD Deaths
From 2015 to 2017, number of opioid-involved overdose deaths increased for nearly all racial/ethnic groups
Pain Control Adequate With Fewer Opioids After Corneal Surgery
After assessment of postoperative opioid use, patients receive fewer opioid tablets but pain is controlled
October 2019 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for October 2019. This roundup includes the latest...
FDA Committee: Makena Should Be Removed From Market
Drug was approved by FDA in 2011 to reduce risk for preterm birth in at-risk women
Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML
Overall survival significantly longer, percentage of remission higher than with salvage chemotherapy
Acute Kidney Injury Often Seen With Checkpoint Inhibitor Use
8 percent of patients receiving checkpoint inhibitor therapy experienced sustained acute kidney injury
